Adaptimmune Therapeutics Presents Positive Data from Phase 2 IGNYTE-ESO Trial at CTOS 2024 Annual MeetingOn November 13, 2024, Adaptimmune Therapeutics plc revealed significant data from the primary analysis of its pivotal Phase 2 IGNY
| ADAP Stock | USD 0.62 0.03 4.62% |
Slightly above 62% of Adaptimmune Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Adaptimmune Therapeutics Plc suggests that many traders are alarmed. Adaptimmune Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Adaptimmune Therapeutics Plc. Many technical investors use Adaptimmune Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Adaptimmune |
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Adaptimmune Therapeuticss 8K filing here. About Adaptimmune Therapeutics Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the
Read at thelincolnianonline.com
 |
Adaptimmune Therapeutics Fundamental Analysis
We analyze Adaptimmune Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptimmune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptimmune Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Adaptimmune Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Adaptimmune Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adaptimmune Therapeutics stock to make a market-neutral strategy. Peer analysis of Adaptimmune Therapeutics could also be used in its relative valuation, which is a method of valuing Adaptimmune Therapeutics by comparing valuation metrics with similar companies.
Peers
Adaptimmune Therapeutics Related Equities
| APTO | Aptose Biosciences | 4.76 | ||||
| STOK | Stoke Therapeutics | 0.45 | ||||
| AFMD | Affimed NV | 0.84 | ||||
| NKTX | Nkarta | 1.67 | ||||
| SGMO | Sangamo Therapeutics | 4.10 | ||||
| AGIO | Agios Pharm | 4.12 | ||||
| ACET | Adicet Bio | 4.17 | ||||
| PLRX | Pliant Therapeutics | 4.76 | ||||
| BDTX | Black Diamond | 4.93 | ||||
| MREO | Mereo BioPharma | 5.59 | ||||
| CRVS | Corvus Pharmaceuticals | 5.66 | ||||
| INKT | Mink Therapeutics | 6.41 | ||||
| LPTX | Leap Therapeutics | 9.73 | ||||
| PDSB | PDS Biotechnology | 10.19 |
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.